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ABSTRACT
The majority of breast cancers (90–95%) arise due to mediators distinct from 
inherited genetic mutations. One major mediator of breast cancer involves chronic 
inflammation. M1 macrophages are an integral component of chronic inflammation 
and the breast cancer tumor microenvironment (TME). Previous studies have 
demonstrated that up to 50% of the breast tumor comprise of tumor-associated 
macrophages (TAMs) and increased TAM infiltration has been associated with poor 
patient prognosis. Furthermore, breast cancer associated deaths are predominantly 
attributed to invasive cancers and metastasis with epithelial-mesenchymal transition 
(EMT) being implicated. In this study, we investigated the effects of cellular crosstalk 
between TAMs and breast cancer using an in vitro model system. M1 polarized THP-
1 macrophage conditioned media (CM) was generated and used to evaluate cellular 
and functional changes of breast cancer lines T47D and MCF-7. We observed that 
T47D and MCF-7 exhibited a partial EMT phenotype in the presence of activated THP-
1 CM. Additionally, MCF-7 displayed a significant increase in migratory and invasive 
properties. We conclude that M1 secretory factors can promote a partial EMT of 
epithelial-like breast cancer cells. The targeting of M1 macrophages or their secretory 
components may inhibit EMT and limit the invasive potential of breast cancer.
INTRODUCTION
Breast cancer is the most common malignancy 
in women within the United States affecting around 1 
in 8 women [1–2] with an estimated number of breast 
cancer cases in 2018 to be 268,670 [1]. Breast cancer is 
also the second leading cause of cancer-related deaths in 
females with approximately 40,450 attributed deaths and 
is second only to lung cancer [1]. These high death rates 
can be primarily attributed to invasive breast cancers that 
metastasize and form secondary tumors [3]. Increased 
breast screenings, newer aggressive therapeutics, 
and a reduction in hormone replacement therapy has 
resulted in a decline in breast cancer deaths since early 
2000; however, metastatic breast cancer is still a major 
challenge [4, 5]. 
Around 5–10% of total breast cancer occurrences are 
a result of inherited genetic mutations (e.g., BRCA1/2), 
which leaves an astounding 90–95% of breast cancers 
that develop due to the influence of outside mediators. 
One major mediator of breast cancer development and 
progression is inflammation. Inflammation is a natural 
biological process that occurs during times of infection or 
wound healing and is self-limiting which is hence called 
acute inflammation. During chronic inflammation this 
self-limiting process is deregulated and can contribute 
to a number of diseases including: Alzheimer’s [6], 
cardiomyopathy [7], osteoarthritis [8], inflammatory 
bowel disease (IBD) [9], and numerous types of 
cancers including breast [10–12]. Specifically, chronic 
inflammation has been associated with cancer initiation 
and progression [13–15].
One significant constituent of chronic inflammation 
is macrophages which are also a main resident of the breast 
tumor microenvironment (TME). Macrophages that reside 
within the TME are termed tumor-associated macrophages 
(TAMs) and have been shown to comprise up to 50% of 
the total tumor mass in certain breast cancer clinical cases 
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with poor prognosis associated with increased TAM tumor 
infiltration [16–18].
Macrophages are subdivided into two distinct 
phenotypes, M1 or M2, depending on specific 
stimuli including cytokines and bacterial moieties. 
M1 macrophages are classically activated and pro-
inflammatory and have traditionally been deemed as anti-
tumor due to their ability to generate reactive nitrogen 
and oxygen intermediates, and pro-inflammatory 
cytokines [19, 20]. On the contrary, M2 macrophages 
are alternatively activated and anti-inflammatory, 
promoting tumor progression by downregulating the 
immune response and stimulating angiogenesis [21, 
22]. Although M1 macrophages are known to have anti-
tumor properties, these immune cells enhance tumor 
development and progression through frequent tissue 
damage and disruption in addition to pro-inflammatory 
cytokines secreted.
Epithelial-mesenchymal transition (EMT) is a 
cellular process where epithelial cells lose adhesive 
properties and cell polarity to become motile and 
mesenchymal-like. Although EMT is known to be a 
natural occurrence serving important roles in development 
[23] and wound healing [24], cancer cells can harness this 
process in ultimately enhancing metastasis. Currently, the 
roles of M1 macrophages influencing breast cancer cells to 
undergo EMT is not widely known or studied.
Our laboratory has previously demonstrated that 
estrogen treated murine mammary breast cancer, and 
human thyroid cancer cells, secrete factors that promote 
human umbilical vein endothelial cell (HUVEC) migration 
and tube formation. These factors are contained within 
the conditioned media generated from these cancer cells. 
[25, 26]. In this study, we used a similar methodology of 
generating conditioned media and investigated the role 
of M1 macrophage secretory factors and their potential 
Figure 1: THP-1 cells exhibit an M1 macrophage phenotype following activation with TPA. (A) THP-1 cells express 
monocyte/macrophage lineage marker CD68. (B) Upon activation with TPA, THP-1 cells express M1 macrophage markers iNOS and IL-
6. Unactivated and activated THP-1 cells were seeded overnight and probed with CD68, iNOS, or IL-6 primary antibodies. Fluorescent 
secondary antibodies were used for immunofluorescence. Pictures were taken using Axiovision Rel 4.8 at 100x magnification. (C) 
Activated THP-1 cells express pro-inflammatory cytokines including: TNF-α, IL-1β, and IL-8. A human inflammation array was performed 
on unactivated or activated THP-1 CM (48 h). Cytokine/chemokine blots were analyzed using ImageJ and optical density determined and 
normalized ± SEM of two independent experiments. 
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in inducing EMT in epithelial-like breast cancer cell 
lines, T47D and MCF-7. We determined that a human 
monocytic cell line, THP-1, when polarized towards an 
M1 phenotype can induce breast cancer cells to undergo 
a partial EMT; thereby, having the potential to stimulate 
breast cancer metastasis. 
RESULTS
Activation of THP-1 with TPA induces an M1 
macrophage phenotype
In order to determine the effects of cellular crosstalk 
between TAMs and breast cancer mediated by macrophage 
secretory factors, the macrophage phenotype of THP-1 
monocytes activated with 12-O-Tetradecanoylphorbel-
13-acetate (TPA) was first identified. Unactivated and 
activated THP-1 were probed for CD68, a transmembrane 
protein which is a common monocyte/macrophage 
lineage marker. Both, unactivated and activated, 
THP-1 cells expressed CD68 validating this cell type 
being of monocyte/macrophage lineage (Figure 1A). 
M1 macrophage markers iNOS and IL-6 were also 
evaluated using immunofluorescence analysis. Activated 
THP-1 cells expressed increased iNOS and IL-6 compared 
to unactivated THP-1 cells (Figure 1B). Additionally, 
an analysis of the cytokine profile of activated THP-1 
cells showed a pro-inflammatory cytokine expression of 
TNF-α, IL-1β, and IL-8 (Figure 1C). This indicates that 
THP-1 cells, upon activation with TPA, promotes an M1 
Figure 2: T47D and MCF-7 cells exhibited spindle-like morphology, decreased E-cadherin, and decreased viability 
viable cells following treatment with activated THP-1 CM. (A) Treatment of T47D and MCF-7 with activated THP-1 CM 
promotes mesenchymal-like morphological changes. Breast cancer cells were treated with unactivated or activated THP-1 CM for 24 h and 
cell morphology was observed by phase contrast microscopy. Pictures were taken at 20x magnification using phase contrast microscopy. 
(B) T47D and MCF-7 were treated for 24 h with control (5% CS-RPMI) or activated THP-1 CM and probed with E-cadherin primary 
antibodies. Fluorescent secondary antibodies in addition to DAPI (nuclear stain) were used for immunofluorescence. Pictures were taken 
using Axiovision Rel 4.8 at 100x magnification. (C) Activated THP-1 CM leads to decreased number of viable T47D and MCF-7 cells at 
24 and 48 h. A trypan blue exclusion assay was performed to evaluate the number of viable cells. Data represents the number of viable cells 
in duplicates ± SEM of two independent experiments.
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macrophage phenotype which is a major contributor to 
chronic inflammation.
Activated THP-1 secretory factors alter breast 
cancer cell morphology and reduces viability
In order to evaluate the effects of activated THP-1 
secretory factors on breast cancer phenotype, we used an 
in vitro model system; T47D and MCF-7 human breast 
cancer cells treated with unactivated or activated THP-1 
conditioned media (CM). T47D and MCF-7 human breast 
cancer cells are of the luminal subtype being estrogen 
receptor positive and Her2 negative and are presumably 
amenable to epithelial-mesenchymal transition. These cell 
lines in their native state in cell culture are epithelial-like. 
Activated THP-1 CM induced spindle-like morphology 
of breast cancer cells compared to unactivated THP-1 
CM or control treatments (Figure 2A). T47D and MCF-
7 are epithelial-like cells and a transition to spindle-like 
morphology, indicates a change in cellular phenotype in 
breast cancer cells, resembling mesenchymal cells. There 
was decreased E-cadherin expression in T47D and MCF-
7 following activated THP-1 CM treatment (Figure 2B). 
A trypan blue exclusion assay was used to determine 
the number of viable breast cancer cells following THP-
1 CM treatments. We observed a significant decrease in 
the number of viable T47D and MCF-7 following 24 h 
treatment with activated THP-1 CM (Figure 2C).
In order to evaluate cellular interactions between 
M1 macrophages and breast cancer cells, we performed 
co-culture experiments with activated THP-1 and breast 
cancer cell lines using 0.4-μM transwell chambers. We 
evaluated cell morphology and the viability. As observed 
with activated THP-1 CM treatments, T47D and MCF-
7 exhibited spindle-like morphology (Figure 3A) and 
a significant decrease in the number of viable cells 
(Figure 3B) in the presence of activated THP-1 cells. 
Thus, activated THP-1 secretory factors are promoting 
a mesenchymal-like phenotype in addition to decreased 
cellular growth of breast cancer cells.
M1 macrophage inflammatory factors 
upregulate epithelial-mesenchymal transition 
related transcription factors 
Spindle-like morphology and reduced viability 
are prominent characteristics of cells undergoing EMT. 
Therefore, we evaluated whether activated THP-1 
secretory factors are promoting the EMT process. We 
assessed EMT transcription factors and markers in 
T47D and MCF-7 treated with activated THP-1 CM 
using Western blot analysis and immunofluorescence. 
We observed increased nuclear localization of EMT 
transcription factors NF-κB and Snail in T47D (Figure 
4A), while MCF-7 displayed increased nuclear localization 
of NF-κB, Snail, and Slug (Figure 4B). MDA-MB 231 
Figure 3: Spindle-like morphology and reduced viability is observed following co-culture with activated THP-1 cells. 
(A) Co-culture of activated THP-1 cells with either T47D or MCF-7 promotes mesenchymal-like morphology. Breast cancer cells were 
co-cultured for 24 h and cell morphology was observed. Pictures were taken at 10x magnification using phase contrast microscopy. (B) 
A decreased number of viable breast cancer cells was observed following co-culture with activated THP-1 cells for 24 h. A trypan blue 
exclusion assay was performed to evaluate viability. Data represents the number of viable cells in duplicates ± SEM of two independent 
experiments in duplicates. 
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that is considered post-EMT was used for comparison 
and displays robust mesenchymal Vimentin and Slug 
expression throughout (Figure 4C). Therefore, M1 
macrophage secretory factors induce EMT transcription 
factor and marker changes. 
M1 macrophage inflammatory factors promote 
MCF-7 migration and invasion in addition to 
increased MMP-9 expression 
Since there was increased nuclear localization of 
EMT transcription factors and decreased E-cadherin 
expression on breast cancer cells, induction of EMT was 
indicative. We evaluated migration and invasion of T47D 
and MCF-7 following activated THP-1 CM treatments 
since these processes are known to be upregulated by cells 
undergoing EMT. Breast cancer cell migration and invasion 
was evaluated using a Boyden chamber assay. Following an 
18 h treatment with activated THP-1 CM, MCF-7 exhibited 
a significant increase in migration and invasion compared 
to untreated controls (Figure 5A, Figure 6A). Additionally, 
a scratch wound assay confirmed an increase in MCF-7 
migratory capability in the presence of activated THP-1 
CM (Figure 5B). T47D did not express significant changes 
in either migration or invasion following similar treatments 
(Figure 5A, Figure 6A).
Cells that have increased migratory and invasive 
capabilities are known to secrete matrix metalloproteinases 
(MMPs) such as MMP-2 and MMP-9 which breakdown 
the extracellular matrix allowing cells to migrate and invade 
tissues [27, 28]. We thus evaluated MMP-9 expression in 
breast cancer cells following activated THP-1 CM treatments 
via Western blot analysis. We observed increased MMP-
9 expression in MCF-7 that correlated with the increased 
migration and invasion as previously shown (Figure 6B). 
Additionally, since there were no observed changes in 
Figure 4: T47D and MCF-7 cells exhibit increased nuclear localization of EMT transcription factors. (A) Increased 
nuclear localization of NF-κB and Snail is observed in T47D. (B) MCF-7 displays increased nuclear localization of NF-κB, Snail, and Slug. 
(C) MDA-MB 231 robustly expresses mesenchymal markers Vimentin and Slug. T47D, MCF-7, and MDA-MB 231 were treated with 
activated THP-1 CM for 6 h, 12 h, 24 h, and 48 h. Nuclear extractions were prepared and Western blots performed probing for: NF-κB (65 
kDa), Slug (30 kDa), Snail (29 kDa), Vimentin (57 kDa), β-Actin (45 kDa), and Lamin (63, 74 kDa). Relative density of NF-κB, Snail, and 
Slug is shown normalized to Lamin loading controls ± SEM of two independent experiments.
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migration or invasion for T47D with M1 secretory factors, 
we did not detect changes in MMP-9 (Figure 6B). Therefore, 
increased MMP-9 expression may contribute to the migratory 
and invasive potential of MCF-7.
DISCUSSION
Chronic inflammation is known to contribute to 
several types of diseases including cancer. One integral 
component of chronic inflammation involves immune 
cells, specifically macrophages. Macrophages are 
divided into M1 or M2 phenotypes and both types have 
been implicated in cancer development or progression. 
Anti-inflammatory cytokines such as IL-4, IL-13, and 
TGF-β may polarize macrophages into M2 phenotypes 
which are considered immunosuppressive and can 
contribute to breast cancer progression by promoting 
growth, metastasis, and angiogenesis. On the contrary, 
IFN-γ, GM-CSF, and LPS can polarize macrophages 
into M1 phenotype. Since the predominant role of M1 
macrophages is related to inflammation and that chronic 
inflammation has a detrimental role in cancer progression, 
this study was focused on M1 macrophage based cellular 
transition. M1 macrophages are pro-inflammatory and 
have been traditionally deemed as having anti-tumor 
activity. However, M1 macrophages through chronic 
inflammation have been associated with cancer initiation 
due to introducing tissue damage [19, 20, 29] and 
cytokine secretion [19, 30, 31]. In addition, the TME of 
numerous types of cancers including breast contain TAMs. 
Therefore, in this study we investigated the influence of 
M1 macrophages on breast cancer cells through cellular 
crosstalk mediated by macrophage secretory factors. 
We determined that cellular crosstalk mediated by M1 
secretory factors promoted EMT of luminal subtypes of 
breast cancer.
Figure 5: THP-1 CM promotes MCF-7 migration. (A) MCF-7 exhibits increased migration at 18 h in the presence of activated 
THP-1 CM. Breast cancer migration was evaluated using Boyden chamber assays. Pictures were taken using brightfield microscopy at 
5x magnification counting four fields per insert. Data is represented as percent migration compared to control in duplicates ± SEM of two 
independent experiments. (B) Scratch wound assay confirms increased MCF-7 migration. Scratch-wound assay was performed on T47D 
and MCF-7 treated with control (5% CS-RPMI) or activated THP-1 CM with mitomycin C (2 μg/mL) for 24 h. Pictures were taken at 0 h, 
24 h, and 48 h following control or CM treatments using phase contrast microscopy and Axiovision Rel 4.8 at 5x magnification. 
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We used an in vitro model system to evaluate the 
interactions between infiltrating macrophages and breast 
cancer as would resemble within the TME. Previous 
studies have demonstrated that human monocytic cell lines 
such as THP-1 when activated with TPA exhibit an M1 
phenotype [32–34]. We generated CM and observed that 
following the activation of THP-1 with TPA, there was 
enhanced expression of M1 marker iNOS in addition to 
pro-inflammatory cytokines IL-6, TNF-α, IL-1β, and IL-8 
when compared to unactivated THP-1.
To evaluate cellular crosstalk mediated by pro-
inflammatory macrophage secretory factors on breast 
cancer cells, we examined the cellular and functional 
changes caused by activated THP-1 CM on luminal/
epithelial-like breast cancer cell lines T47D and MCF-
7. We observed that activated THP-1 secretory factors 
induced EMT-like features in breast cancer cells. T47D 
and MCF-7 exhibited mesenchymal-like morphology and 
decreased viability following activated THP-1 CM and 
co-culture experiments. In addition, there was increased 
nuclear localization of EMT-related transcription factors 
for T47D and MCF-7. EMT-related transcription factors 
have functional roles in downregulating epithelial 
markers such as E-cadherin which is a component of 
adherens junctions and disruption of this protein promotes 
increased migratory capability of cells [35, 36]. We 
evaluated E-cadherin expression in breast cancer cells 
following activated THP-1 CM treatment. There was a 
loss of E-cadherin in spindle-like T47D and MCF-7 cells 
following treatments. Decreased E-cadherin expression 
would subsequently influence breast cancer cell motility 
warranting an inquiry into  cell migration and invasion. 
Cell migration and invasion are processes that are 
identified as being upregulated in cells undergoing EMT. 
We observed that activated THP-1 CM promoted MCF-
7 to demonstrate significantly increased migration as 
observed through Boyden chamber and scratch wound 
assays. Additionally, there was increased invasion and 
MMP-9 expression by MCF-7. T47D did not display 
changes in migration or invasion in the presence of 
activated THP-1 CM compared to control. As was 
previously shown, T47D displayed an increase in Snail 
nuclear localization which was observed to be oscillatory 
through 48 h. The irregular nuclear localization of Snail 
and the absence of Slug may have negatively affected 
T47D migratory and invasive properties as opposed to 
MCF-7 in which Snail and Slug expression was dynamic. 
Therefore, MCF-7 displayed a more progressed EMT 
compared to T47D. 
Several studies have formerly established a link 
between inflammatory factors and cancer EMT [37–40]. 
Pro-inflammatory cytokines such as TNF-α have been 
previously demonstrated to induce EMT in a number of 
cancers including breast cancer [41, 42]. TNF-α has been 
shown to stimulate the induction of EMT transcription 
factors including Snail, Slug, Twist, and ZEB1/2 through 
NF-κB signaling [41, 43]. It is possible that TNF-α which 
is secreted by activated THP-1 promotes the induction of 
EMT as observed in T47D and MCF-7. Further studies 
examining the neutralization of TNF-α in activated THP-1 
CM and the effects on EMT induction should be carried out.
Other cytokines that have been implicated in EMT and 
were present in activated THP-1 CM include: IL-1β [44], IL-6 
[45], IL-8 [46] and TGF-β [47]. Additionally, the influence of 
macrophage secreted exosomes containing miRNA cargo was 
not evaluated. Exosomes are small (30-120 nm) membraneous 
nanovesicles that are secreted from cells and have been 
implicated in cell-cell communication [48]. Depending on 
the cell type, exosomes can contain various types of cargo 
including miRNA. Several studies have reported that miRNA 
Figure 6: Activated THP-1 CM treatment enhances MCF-7 invasion and MMP-9 expression. (A) MCF-7 exhibits increased 
invasion at 18 h in the presence of activated THP-1 CM. Breast cancer invasion was evaluated using Boyden chamber assays. Pictures were 
taken using brightfield microscopy at 5x magnification counting four fields per insert. Data is represented as percent invasion compared to 
control in duplicates ± SEM of two independent experiments. (B) There is increased expression of MMP-9 by MCF-7 with 24 h activated 
THP-1 CM treatment. MMP-9 (84, 92 kDa) and GAPDH (37 kDa) expression was evaluated using Western blots. 
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can contribute to EMT [49, 50]. Therefore, it is possible that 
macrophage secreted exosomes containing particular miRNA 
may promote EMT as observed with T47D and MCF-7.
We demonstrate that pro-inflammatory secretory 
factors can induce a partial EMT in breast cancer cells, 
displaying a combination of epithelial and mesenchymal 
characteristics. Additionally, certain breast cancer cell lines 
may be more prone to undergoing EMT compared to others. 
In our study, we observed that MCF-7 exhibited increased 
EMT properties compared to T47D following similar 
treatments. Breast cancer cells that undergo EMT have a 
greater likelihood of contributing to metastasis, decreasing 
survival outcomes for patients. Additionally, breast cancer 
cells that have been shown to undergo EMT may not only 
contribute to increased metastasis, but may become resistant 
to cytotoxic T lymphocytes [51]. Therefore, the degree 
of tumor cell EMT can potentially affect how a patient 
may or may not respond to immunotherapy which has an 
important implication in patient treatment. Further it should 
be noted that epithelial-mesenchymal transition has inherent 
plasticity which is well integrated with stem cell population 
generation, [52] and has considerable redundancies as all 
factors, mediators and signal transducers are not induced 
concurrently. 
We propose that by directly targeting M1 
macrophages or neutralizing pro-inflammatory secretory 
factors, the chronic inflammatory response may be limited 
and potentially reduced ultimately hindering breast cancer 
progression. By reducing breast cancer invasive potential 
through the inhibition of EMT processes, the risk of 
metastasis decreases and the prospect of patient survival 
increases. A better understanding of the cells found within 
the TME and how they impact breast cancer progression 
will help in terms of breast cancer therapy. 
MATERIALS AND METHODS
Cells and cell culture
The breast cancer cell lines used include: T47D 
and MCF-7 which were obtained from American Type 
Culture Collection (ATCC). T47D and MCF-7 cells 
were grown in RPMI-1640 (Mediatech, Herndon, VA) 
and DMEM-1640, respectively, supplemented with 10% 
fetal bovine serum (FBS) (Atlanta Biologicals, Atlanta, 
GA), penicillin 10,000 IU/mL, streptomycin 10,000 μg/
mL (Mediatech) and 2 mM L-glutamine (Mediatech). 
Human monocytic cell line, THP-1, was grown in 
RPMI-1640 (Mediatech, Herndon, VA), supplemented 
with 10% FBS (Atlanta Biologicals, Atlanta, GA), 
penicillin 10,000 IU/mL, streptomycin 10,000 ug/mL 
(Mediatech), 2 mM L-glutamine (Mediatech), and 0.05 
mM 2-mercaptoethanol. T47D, MCF-7, and THP-1 cell 
lines were purchased between 2000 to 2013 and were 
authenticated by the Genomics Core at Albert Einstein 
School of Medicine using SoftGenetics GeneMarkerHID. 
Differentiation of THP-1 and generation of 
conditioned media
THP-1 monocytes were seeded at a density of 5x106 
cells and treated with 200 nM 12-O-Tetradecanoylphorbel-
13-acetate (TPA) in RPMI-1640 supplemented media 
for THP-1 as specified above. The media was discarded 
and rinsed with phenol red free RPMI-1640 following 
incubation for 48 h. THP-1 cells were further incubated 
for 48 h in 5% charcoal-stripped RPMI to obtain THP-
1 macrophage conditioned media (CM). The conditioned 
media was then collected and centrifuged for 5 min at 
1500 rpm to remove cells and cell debris. Conditioned 
media was stored in -80°C until future use.
Morphology analysis
T47D and MCF-7 were seeded in 6 well plates at 
3x105 per well in duplicates and allowed to adhere and 
grow overnight in RPMI or DMEM media as previously 
described, respectively. Seeding media was removed from 
the cell monolayer and rinsed with phenol-red free RPMI. 
Breast cancer cells were treated with either 5% charcoal-
stripped phenol-red free RPMI as control, unactivated 
THP-1 CM, or activated THP-1 CM for CM evaluation for 
24 h. Pictures were taken under phase contrast microscopy 
at 20× magnification. 
Trypan blue exclusion assay
T47D and MCF-7 were seeded in 6 well plates at 3 × 
105 per well in duplicates and allowed to adhere and grow 
overnight in RPMI or DMEM culture media as previously 
described, respectively. Seeding media was removed from 
the cell monolayer and rinsed with phenol-red free RPMI. 
Breast cancer cells were treated with either 5% charcoal-
stripped phenol-red free RPMI, unactivated THP-1 CM, or 
activated THP-1 CM for 24 or 48 h. Following respective 
time points, cells were harvested and stained using 0.4% 
trypan blue (Sigma Chemical). Viable (unstained) cells 
were counted using a hemocytometer. 
Co-culture experiments
THP-1 were activated using TPA for 48 h and seeded 
in 0.4-μm transwell 6-well plates (CorningTM CostarTM) 
at 1 × 106 cells per well in duplicates. T47D and MCF-7 
were seeded in 6 well plates at 3 × 105 cells per well in 
duplicates and allowed to adhere and grow overnight in 
RPMI or DMEM culture media as previously described. 
Seeding media was removed from the cell monolayer and 
rinsed with phenol-red free RPMI. Activated THP-1 were 
rinsed with phenol-red free RPMI. Breast cancer cells 
were incubated with 5% charcoal-stripped phenol-red free 
RPMI. 0.4-μm transwells for controls and activated THP-
1 contained 5% charcoal-stripped phenol-red free RPMI 
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and respective co-cultures transpired for 24 h. Morphology 
pictures were taken using phase contrast microscopy at 
10× magnification. Viable cells were determined using 
trypan blue exclusion assay as mentioned above. 
Western blot analysis of total cell or subcellular 
fractionated lysates 
The generation of total cell lysates or subcellular 
fractionated lysates was prepared by two different 
methods.
Total cell lysates 
Following activated THP-1 CM treatments, breast 
cancer cells were harvested and lysates generated using 
RIPA Lysis Buffer (50 mM Tris-HCL pH 7.5, 150 mM 
NaCl, 1% NP-40, 0.5% Sodium deoxycholate, 0.1% SBS) 
with HaltTM Protease and Phosphatase Inhibitor Cocktail 
(1X Concentration) (Life Technologies). Membranes were 
blocked with 5% milk in TBST (10 mM Tris-HCL, pH 
7.5, 200 mM NaCl, 0.05% Tween-20) for 2 h at room 
temperature and then incubated overnight in primary 
antibodies: MMP-9 (Cell Signaling) and GAPDH (Cell 
Signaling). Membranes were washed 3 times for 10 min 
per wash and incubated with secondary antibodies of goat 
anti-rabbit IgG (H+L) Horseradish Peroxidase (Thermo 
Scientific) for 2 h at room temperature.
Subcellular fractionated lysates 
Following activated THP-1 CM treatments, breast 
cancer cells were harvested and cytoplasmic and nuclear 
protein extracts generated using NE-PER Nuclear and 
Cytoplasmic Extraction Reagents (Thermo Scientific) 
as per manufacturer’s instruction with HaltTM Protease 
and Phosphatase Inhibitor Cocktail (1X Concentration) 
(Life Technologies). Membranes were blocked with 
5% milk in TBST (10 mM Tris-HCL, pH 7.5, 200 mM 
NaCl, 0.05% Tween-20) for 2 h at room temperature 
and then incubated overnight in primary antibodies of 
either: NF-κB (Cell Signaling), Snail (Cell Signaling), 
Slug (Cell Signaling), and Lamin A/C (Cell Signaling) 
at 4°C. Membranes were washed 3 times for 10 min per 
wash and incubated with secondary antibodies of either 
goat anti-rabbit IgG (H+L) Horseradish Peroxidase 
(Thermo Scientific) or rabbit anti-mouse IgG (H+L) 
Horseradish Peroxidase (Thermo Scientific) for 2 h at 
room temperature.
Migration and invasion assays
BD Biocoat Control Inserts (BD Biosciences) 
and BD Biocoat Matrigel Invasion Chambers (BD 
Biosciences) with 8-μm pore membrane filters were 
used for the migration and invasion assays, respectively. 
Matrigel inserts were rehydrated for 2 h, 37°C with 
phenol-red free RPMI. Inserts were then incubated with 
2.5 × 104 cells/0.5 mL of T47D or MCF-7 in the presence 
of 5% charcoal-stripped phenol-red free RPMI (control) 
or 48 h activated THP-1 CM with 10% charcoal-stripped 
RPMI in the chamber as the chemoattractant. Following 
18 h treatments at 37°C, 5% CO2 atmosphere, the removal 
of non-migrating/invading cells on the upper surface was 
performed through scraping with a cotton swab. Cells 
were fixed with 100% methanol for 2 min and stained with 
1% Toluidine Blue in 1% Borex for 2 min. Excess stain 
was removed through rinsing the inserts in distilled water 
and allowed to dry overnight. Pictures were taken using 
PixeLINK Megapixel FlatWire Camera Release 3.2 on the 
Axiovert 200 M microscope (Carl Zeiss MicroImaging, 
Inc., Thornwood, NY) at 5x magnification counting four 
fields per insert.
Scratch-wound assay
Migration was assessed for T47D and MCF-7 using 
a scratch-wound assay. Cells were seeded in 6 well plates 
at 5 × 105 cells per well in duplicates in RPMI or DMEM 
media as previously described. Cells were allowed to 
adhere and grow to 60–75% confluent cell monolayers. 
Two vertical wounds were created using a 10 μL sterile 
pipette tip followed by removal of detached cells and 
cell debris by rinsing with phenol-red free RPMI. The 
wounded cell monolayer was treated with either 5% 
charcoal-stripped phenol-red free RPMI or activated 
THP-1 CM with mitomycin C (2 μg/mL) for 24 h. Phase 
contrast microscopy captured pictures at 0 h and 24 h 
following treatments using Axiovision Rel 4.8 on the 
Axiovert 200 M microscope (Carl Zeiss MicroImaging, 
Inc., Thornwood, NY) at 5× magnification.
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